Upload your resume. PhdFit's six research agents compare your background with faculty profiles, recent publications, lab focus, and outreach opportunities, then rank professors with evidence you can review.
Ask how her lab is extending interpretability methods into fairness audits for real-world AI systems.

University of Pennsylvania · Rehabilitation Medicine
Active 1997–2024
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
Circulation · 2023 · 147 citations
BACKGROUND: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet alfa in patients with acute major bleeding. The results of the final analyses are presented. METHODS: Patients with acute major bleeding within 18 hours of FXa inhibitor administration were enrolled. Co-primary end points were anti-FXa activity change from baseline during andexanet alfa treatment and excellent or good hemostatic efficacy, defined by a scale used in previous reversal studies, at 12 hours. The efficacy population included patients with baseline anti-FXa activity levels above predefined thresholds (≥75 ng/mL for apixaban and rivaroxaban, ≥40 ng/mL for edoxaban, and ≥0.25 IU/mL for enoxaparin; reported in the same units used for calibrators) who were adjudicated as meeting major bleeding criteria (modified International Society on Thrombosis and Haemostasis definition). The safety population included all patients. Major bleeding criteria, hemostatic efficacy, thrombotic events (stratified by occurring before or after restart of either prophylactic [ie, a lower dose, for prevention rather than treatment] or full-dose oral anticoagulation), and deaths were assessed by an independent adjudication committee. Median endogenous thrombin potential at baseline and across the follow-up period was a secondary outcome. RESULTS: =0.003). Median endogenous thrombin potential was within the normal range by the end of andexanet alfa bolus through 24 hours for all FXa inhibitors. CONCLUSIONS: In patients with major bleeding associated with the use of FXa inhibitors, treatment with andexanet alfa reduced anti-FXa activity and was associated with good or excellent hemostatic efficacy in 80% of patients. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02329327.
Vishesh Kumar
Post Graduate Institute of Medical Education and Research
Lorraine V. Kalia
University of Ottawa
Ahmed Elzanaty
University of Toledo
Neeraj Saini
The University of Texas MD Anderson Cancer Center
C. Jones
Danylo Halytsky Lviv National Medical University
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
Sapan Bhuta
The Ohio State University Wexner Medical Center
Nathan Van Houzen
Harvard University
Mitra Patel
University of Toledo